Literature DB >> 17222201

In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results.

Susan E Rodgers1, Elizabeth M Duncan, Denise M Barbulescu, Diana M Quinn, John V Lloyd.   

Abstract

In some mild haemophilia A patients (discrepant haemophilia), factor VIII coagulant activity (FVIII:C) levels, by one-stage assay are more than double than those by two-stage assay. This may be due to the longer incubation times (10-12 min) in the two-stage assay. This study aimed to determine the time course of the activation phase of the two-stage assay, using both classical coagulation and chromogenic detection methods. In both systems, for equivalent patients (equivalent FVIII:C levels by one-stage and two-stage assays, n = 6, all different mutations), similar FVIII:C results were obtained with short- or long-incubation times. In contrast, plasma from discrepant patients (n = 8, five different mutations) showed higher FVIII:C at shorter incubation times than after longer incubation times. In the chromogenic assay, FVIII:C levels were higher after incubation for 2 min (23-56%, mean 41%) than after 10 min (19-41%, mean 29%). In the classical coagulation assay, FVIII:C levels were higher at shorter incubation times (21-64%, mean 37%) than with the longer incubation times usually used (13-29%, mean 23%). These time-course experiments have verified that the longer incubation time used in the two-stage assay is at least partly responsible for the lower FVIII:C measured by that assay in discrepant haemophilia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17222201     DOI: 10.1111/j.1365-2141.2006.06402.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  The "normal" factor VIII concentration in plasma.

Authors:  Saulius Butenas; Behnaz Parhami-Seren; Anetta Undas; David N Fass; Kenneth G Mann
Journal:  Thromb Res       Date:  2010-05-07       Impact factor: 3.944

2.  Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients.

Authors:  Tarek M Owaidah; Hazzaa A Alzahrani; Nouf S Al-Numair; Abdulmjeed O Alnosair; Amelita M Aguilos; Mahasen Saleh
Journal:  Adv Hematol       Date:  2020-09-09

Review 3.  Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B.

Authors:  Richard A Marlar; Karin Strandberg; Midori Shima; Dorothy M Adcock
Journal:  Eur J Haematol       Date:  2019-11-13       Impact factor: 2.997

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.